Clinical Trial Result Information

Title of Study:
A phase IV, randomised, multicentre, efficacy and safety study examining the effect of induction dosing with the combination of peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C infected with hepatitis C genotype 1

Fast Facts:

Protocol number:	ML17908
Sponsor:	Roche Products Pty Ltd
Company division:	Pharmaceutical
Product name:	PEGASYS
Generic name:	peginterferon alfa-2a (40KD)
Phase of development:	IV
Therapeutic area, approved indication:	Hepatitis C, Chronic
Date of report:	To be Published

Clinical study summary:
This trial does not yet have clinical trial results posted on this website. All trial results will be posted within one year of approval or one year after trial completion, unless the release of information is restricted due to journal publication timing or pending regulatory filing. For further information on the timing of posting clinical trial results please consult the Roche policy for posting information on this website.

Click here for the protocol registry listing of this trial.